Effects of Adding an Oculomotor Therapy Treatment in Patients With Migraine

September 15, 2023 updated by: Alexander Achalandabaso, University of Jaén

Effects of Adding an Oculomotor Therapy Treatment to a Cervical Protocol in Patients With Migraine

Headaches are the fourth cause/reason for disability in the world population. Of which, headache in general accounts for 47%, 38% are tension headaches, 10% migraines and 3% for chronic headache lasting more than 15 days a month.

Migraine is a neurological disease/disorder originating in the central nervous system with difficulty modulating responses to common sensory stimuli.

Different studies have linked possible oculomotor problems and headaches, being an important and complex relationship.

It is difficult to find a suitable and beneficial treatment for the treatment of migraine. It is hypothesized that adding a treatment of manual therapy and therapeutic exercise of the oculomotor system to an already established protocol of manual therapy and therapeutic exercise of the cervical region, has an additional benefit for patients with migraines (in relation to the quality of life, symptomatology and functionality).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Migraine is a neurological disease/disorder originating in the central nervous system with difficulty modulating responses to common sensory stimuli. It is characterized by being unilateral, frontotemporal, pulsatile, of moderate or severe intensity, nausea and/or vomiting, sensitivity to movement, visual, auditory, and other afferent stimuli may appear. In addition, other symptoms such as fatigue, neck stiffness, decreased concentration, mood swings and yawning may appear, and the headache may be anticipated up to 48 hours.

It has been hypothesized that the possible relationship between the eyes and the pathophysiology of migraine is due to the trigeminal-cervical complex, since if there is an alteration it would be established by a nociceptive impulse that can trigger central sensitization in the trigeminal nuclei.

Today, the quintessential treatment is pharmacological where the excessive use of medications can trigger possible side effects such as depression, anxiety, weight gain, fatigue and drowsiness, among others, causing an alteration in the patient's quality of life more than of the migraine attack.

Several studies show that there are other non-pharmacological treatment options such as manual physiotherapy and therapeutic exercise for migraines, and that it is effective for reducing the intensity and frequency of attacks, the use of medication and improving the quality of life. Being preventive treatments in order to avoid the frequency and intensity of these attacks.

At present, the role of oculomotricity in headache, although it may be promising, has not been extensively studied. In the literature that the investigators have reviewed, the investigators have found very few studies that investigate manual therapy directly on the eyeball, despite the great relationship of the trigeminal-vascular nerve with migraines and how it influences the different variables.

The main objective of the present study is to investigate the impact and possible additional benefits of adding an oculomotor treatment to a manual therapy protocol of the cervical region in patients with migraine.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain
        • Physiotherapy Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 18-65 years
  • Suffer less than 15 days of headache per month,
  • The pain must have these characteristics: unilateral, pulsating, of moderate to severe intensity, during the attack, nausea and/or vomiting, with the possible presence of an aura
  • History of evolution of more than a year,
  • Onset and aggravation in the afternoon and
  • Relation to visual work
  • Feeling of eye discomfort,
  • Photophobia
  • Neck pain after attack.

Exclusion Criteria:

  • Receiving some type of preventive physiotherapy treatment at the time of the intervention
  • Subjects with preventive medication, pregnancy or lactation, with neurological, systemic or psychiatric disorders, suffering from bone degeneration
  • Metabolic or musculoskeletal problems that could imply risk of the vertebral artery
  • Dizziness
  • Unbalanced tension
  • Use of specific medication
  • Lack of fluency in Spanish.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Cervical treatment
A treatment of the cervical region will be done for 6 weeks, once a week, and they will be taught exercises to do at home.
6 weeks of treatment
Experimental: Oculomotor treatment
An oculomotor treatment will be added to the treatment of the cervical group with specific exercises in the area. Once a week during 6 weeks
6 weeks of treatment
6 weeks of treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the impact
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Headache Impact Test (HIT-6) Questionnaire
Baseline, 6 weeks and 3 months after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the pain
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Visual Analog Scale (VAS). Each item is scored 0-10 (0= no pain; 10= the major pain that the patient can imagine) yielding a total between 0 and 10.
Baseline, 6 weeks and 3 months after intervention
Changes in the disability
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Migraine Disability Assessment (MIDAS) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the depression
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Patient Health Questionnaire (PHQ-9) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the anxiety
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Generalized Anxiety Disorder (GAD-7) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the sleep quality
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Pittsburgh Sleep Quality Index (PSQI) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the kinesiophobia
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Tampa Scale of Kinesiophobia (TSK-11) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the catastrophizing
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Pain Catastrophizing Scale (PCS) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the central sensitization
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Central Sensitization Inventory (CSI) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the neck disability
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Neck Disability Index (NDI) Questionnaire
Baseline, 6 weeks and 3 months after intervention
Changes in the head repositioning
Time Frame: Baseline, 6 weeks and 3 months after intervention

Using the Head Repositioning. This test will be used to assess the subject's proprioceptive ability to reposition the head on the trunk in the horizontal and sagittal planes and to measure the impact of treatment techniques.

The distance between the center of the objective (target) and the laser point is measured, representing the cervico-cephalic positioning error

Baseline, 6 weeks and 3 months after intervention
Changes in the strength of the deep cervical flexors
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Grimmer Test
Baseline, 6 weeks and 3 months after intervention
Changes in the ocular movement
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using Smooth tracking test. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H".
Baseline, 6 weeks and 3 months after intervention
Changes in the ocular movement with variation of the head
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Smooth Pursuit Neck Torsion. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H" with variant head position
Baseline, 6 weeks and 3 months after intervention
Changes in the range of movement
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Cervical Range of Motion Instrument
Baseline, 6 weeks and 3 months after intervention
Changes in the quality of life
Time Frame: Baseline, 6 weeks and 3 months after intervention
Using the Short-Form 12 Health Survey (SF-12). Composed of twelve items, eight dimensions (physical function, physical role, bodily pain, mental health, general health, vitality, social function, and emotional role). The score ranges from 0 to 100, where the higher score implies a better health-related quality of life.
Baseline, 6 weeks and 3 months after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Alexander Achalandabaso, PhD, University of Jaen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2023

Primary Completion (Actual)

May 30, 2023

Study Completion (Actual)

September 15, 2023

Study Registration Dates

First Submitted

February 7, 2023

First Submitted That Met QC Criteria

May 1, 2023

First Posted (Actual)

May 6, 2023

Study Record Updates

Last Update Posted (Actual)

September 18, 2023

Last Update Submitted That Met QC Criteria

September 15, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine

Clinical Trials on Cervical

Subscribe